Bidness Etc |
FDA OKs New Once-Daily Asthma Treatment
WebMD Arnuity Ellipta has been tested in more than 3,600 people with asthma, the company says in a statement. The most common side effects (reported in at least 5% of people) were upper respiratory tract infection, common cold, headache, and bronchitis. GlaxoSmithKline grabs FDA approval for its latest asthma treatment GSK's Asthma Treatment Gets FDA Approval FDA OKs New Maintenance Asthma Treatment Arnuity Ellipta |
View full post on asthma – Google News